Healthy Clinical Trial
Official title:
Phase I, Randomized, Open-Label, Single-Dose, Three Period, Six-Sequence Crossover Study to Determine the Relative Bioavailability of the Evobrutinib Intended Commercial Tablet Formulation (TF2) Compared to the Clinical Tablet Formulation (TF1) and Evaluate the Effect of Food on TF2 Bioavailability in Healthy Participants
The study will evaluate the relative bioavailability (rBA) of the intended commercial tablet formulation (Test Treatment, TF2) of Evobrutinib compared to the clinical tablet formulation (Reference Treatment, TF1) of Evobrutinib and to assess the effect of food on the bioavailability of the intended commercial tablet formulation of Evobrutinib.
Status | Completed |
Enrollment | 18 |
Est. completion date | June 23, 2020 |
Est. primary completion date | June 23, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Participants are overtly healthy as medical evaluation, including no clinically significant abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion - Male or female participants agree to be consistent with local regulations on contraception methods - Female participants are not pregnant or breastfeeding, and at least one of the following condition applies: - Not a WOCBP or - If a WOCBP, use a highly effective contraceptive method (that is, with a failure rate of <1 percent per year, preferably with low user dependency for the following time period: - Before the first dose of the study intervention, if using hormonal contraception: - Has completed at least one 4-week cycle of an oral contraception pill and either had or has begun her menses or - Has used a depot contraceptive or extended-cycle oral contraceptive for least 28 days and has a documented negative pregnancy test using a highly sensitive assay and - A barrier method - During the intervention period - After the study intervention period (that is after the last dose of study intervention is administered) for at least 90 days, plus 30 days (a menstrual cycle) after the last dose of study intervention and agree not to donate eggs (ova, oocytes) for reproduction during this period. The Investigator evaluates the effectiveness of the contraceptive method in relationship to the first dose of study intervention - Females have a negative serum pregnancy test at the Screening Visit and within 24 hours before the first dose of study intervention - The Investigator reviews the medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a female with an early undetected pregnancy - Participants are stable non-smokers for at least 3 months preceding screening - Other protocol defined inclusion criteria could apply. Exclusion Criteria: - History or presence of clinically relevant respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders. - Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery within 6 months prior to screening - History of any malignancy - History of chronic or recurrent acute infection or any bacterial, viral, parasitic or fungal infections within 30 days prior to screening and at any time between screening and admission, or hospitalization due to infection within 6 months prior to screening - History of shingles within 12 months prior to screening - History of drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients - History of alcoholism or drug abuse within 2 years prior to screening, or evidence of such abuse as indicated by the laboratory assays conducted during screening - History of residential exposure to tuberculosis, or a positive QuantiFERON® test within 4 weeks prior to screening - Administration of live vaccines or live-attenuated virus vaccines within 3 months prior to screening - Any condition, including findings in the laboratory tests, medical history, or other screening assessments, that in the opinion of the Investigator constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study's objectives, conduct, or evaluation - Other protocol defined exclusion criteria could apply. |
Country | Name | City | State |
---|---|---|---|
Germany | Nuvisan GmbH | Neu-Ulm |
Lead Sponsor | Collaborator |
---|---|
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib Under Fasted Conditions | Pre-dose up to 24 hours post-dose on Day 6 | ||
Primary | Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-inf) of Evobrutinib Under Fasted Conditions | Pre-dose up to 24 hours post-dose on Day 6 | ||
Primary | Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Under Fasted Conditions | Pre-dose up to 24 hours post-dose on Day 6 | ||
Primary | Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib Under Fed Conditions | Pre-dose up to 24 hours post-dose on Day 6 | ||
Primary | Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-inf) of Evobrutinib Under Fed Conditions | Pre-dose up to 24 hours post-dose on Day 6 | ||
Primary | Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Under Fed Conditions | Pre-dose up to 24 hours post-dose on Day 6 | ||
Secondary | Number of Participants With Treatment -Emergent Adverse Events (TEAEs) Based on Severity Under Fasted Conditions | Day 1 up to Day 6 | ||
Secondary | Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings Under Fasted Conditions | Number of participants with clinically significant change from baseline in vital signs, laboratory parameters and electrocardiogram findings will be reported | Day 1 up to Day 6 | |
Secondary | Area Under the Plasma Concentration-Time Curve From Time Zero to Time 24 Hours After Evobrutinib Administration (AUC0-24) | Pre-dose up to 24 hours post-dose on Day 6 | ||
Secondary | Area Under The Plasma Concentration-Time Curve From Time Zero to Time 12 Hours After Evobrutinib Administration (AUC0-12) | Pre-dose up to 12 hours post-dose on Day 6 | ||
Secondary | Time to Reach Maximum Plasma Concentration (Tmax) of Evobrutinib | Pre-dose up to 24 hours post-dose on Day 6 | ||
Secondary | Time Prior to the First Measurable (non-zero) Concentration (t lag) of Evobrutinib | Pre-dose up to 24 hours post-dose on Day 6 | ||
Secondary | Terminal First Order (elimination) Rate Constant (?z) of Evobrutinib | Pre-dose up to 24 hours post-dose on Day 6 | ||
Secondary | Apparent Elimination Half Life (t1/2) of Evobrutinib | Pre-dose up to 24 hours post-dose on Day 6 | ||
Secondary | Apparent Total Body Clearance (CL/f) of Evobrutinib | Pre-dose up to 24 hours post-dose on Day 6 | ||
Secondary | Apparent Volume of Distribution During Terminal Phase (VZ/f) of Evobrutinib | Pre-dose up to 24 hours post-dose on Day 6 | ||
Secondary | Relative Bioavailability of Test Treatment in Relation to Reference Treatment (Frel) | Pre-dose up to 24 hours post-dose on Day 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |